Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

667.10INR
31 Oct 2014
Price Change (% chg)

Rs16.55 (+2.54%)
Prev Close
Rs650.55
Open
Rs654.00
Day's High
Rs671.95
Day's Low
Rs647.00
Volume
152,667
Avg. Vol
216,616
52-wk High
Rs671.95
52-wk Low
Rs366.70

CIPL.BO

Chart for CIPL.BO

About

Cipla Limited is a pharmaceutical company. During the fiscal year ended March 31, 2012 (fiscal 2012), it introduced a number of new drugs and formulations, such as Adgain (vital nutritional supplement for hair loss); Capnea (caffeine citrate injection and oral solution) for apnoea of prematurity in infants; Caspogin (caspofungin... (more)

Overall

Beta: 0.54
Market Cap (Mil.): Rs535,187.31
Shares Outstanding (Mil.): 802.92
Dividend: 2.00
Yield (%): 0.30

Financials

  CIPL.BO Industry Sector
P/E (TTM): 38.56 32.70 33.67
EPS (TTM): 17.28 -- --
ROI: -- 18.12 17.39
ROE: -- 18.79 18.21
Search Stocks

Cipla asks India to revoke Novartis patents on respiratory drug

MUMBAI - Generic drugmaker Cipla Ltd said on Thursday it has asked the Indian government to revoke five patents held by Swiss firm Novartis AG on respiratory drug Onbrez and has launched a cheaper copy to boost access in the local market.

30 Oct 2014

Cipla asks India to revoke Novartis patents on respiratory drug

MUMBAI - Generic drugmaker Cipla Ltd said on Thursday it has asked the Indian government to revoke five patents held by Swiss firm Novartis AG on respiratory drug Onbrez and has launched a cheaper copy to boost access in the local market.

30 Oct 2014

UPDATE 1-Cipla asks India to revoke Novartis patents on respiratory drug

* Cipla says launched cheaper copy of Novartis drug in Delhi

30 Oct 2014

India's Cipla asks government to revoke Novartis patents on respiratory drug

MUMBAI, Oct 30 - Generic drugmaker Cipla Ltd said on Thursday it had requested the Indian government to revoke five patents held by Swiss firm Novartis AG on respiratory drug Onbrez, to boost its access in the Indian market.

30 Oct 2014

INDIA PRESS-Cipla asks government to revoke five patents held by Novartis - Economic Times

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Derek Francis in Bangalore)

30 Oct 2014

Drugmaker Cipla to set up manufacturing plant in Iran

MUMBAI - Generic drugmaker Cipla Ltd has agreed to set up a manufacturing plant in Iran, as part of its strategy to boost its presence in the country's $4 billion pharmaceuticals market that is growing at about 13 percent annually.

07 Oct 2014

Indian drugmaker Cipla to set up manufacturing plant in Iran

MUMBAI, Oct 7 - Indian generic drugmaker Cipla Ltd has agreed to set up a manufacturing plant in Iran, as part of its strategy to boost its presence in the country's $4 billion pharmaceuticals market that is growing at about 13 percent annually.

07 Oct 2014

Exclusive - India set to run out of critical free drug for HIV/AIDS programme

NEW DELHI - India could run out of a critical medicine in its free HIV/AIDS drugs programme in three weeks due to bureaucratic bungling, a senior government official said, leaving more than 150,000 sufferers without life-saving drugs for about a month.

01 Oct 2014

UPDATE 2-India caps prices of 36 more drugs to improve access -govt official

* Local firms Cipla, Ranbaxy, Cadila among companies affected

19 Sep 2014

Cipla grants Salix rights for Rifaximin

MUMBAI - Drugmaker Cipla Ltd has agreed to grant U.S.-based Salix Pharmaceuticals Ltd rights relating to the "Rifaximin complexes" patent family controlled by Cipla, the two companies said on Thursday.

18 Sep 2014

Earnings vs. Estimates

Search Stocks